Breaking News on Biopharmaceutical Development & Manufacturing

Hot Topics > Emerging Markets

Breaking biopharmerging business news

Emerging Markets

While the US, Japan and Europe are still the main focus for biopharma firms, improving healthcare standards around the world is driving demand for new biopharmaceutical products in emerging markets. 

Dispatches from Interphex Japan

Tokyo drift? Large molecule R&D shortfall threat to Japanese pharma, says Chugai

28-Jun-2017 - A failure to embrace biologics R&D has restricted Japanese pharma’s global growth, says CEO of Roche subsidiary Chugai Pharmaceuticals.

Ex-PM David Cameron tells BIO 2017 not to worry about Brexit effect on employees

21-Jun-2017 - Didn’t make it to San Diego this year? Well neither did we, but still we bring you the best BIO 2017 has to offer.

Consolidated vaccine sector urgently needs a workforce booster shot, Sanofi

16-May-2017 - Long life-cycles and significant consolidation in the manufacturing space have led to a lack of skilled workers in the vaccine space, says Sanofi Pasteur.

UK biopharma industry looks to Switzerland ahead of impending Brexit

28-Mar-2017 - The UK BioIndustry Association will visit Switzerland ahead of Brexit negotiations to learn how to work in Europe without being in the EU.

Saudi CDMO’s fill/finish plant to offer Big Biopharma access to local benefits

01-Feb-2017 - Saudi Biotech Manufacturing has selected Swedish engineering firm KeyPlants to design and build a fill/finish plant for biological APIs.

Trump's TPP withdrawal a boon for Asian biosimilar makers?

Trump, TPP and America First threaten US biomanufacturing jobs, says expert

27-Jan-2017 - Donald Trump’s withdrawal from the Trans-Pacific Partnership (TPP) could end up benefitting Asian biosimilar makers and reducing US jobs, says an IP lawyer.

Valeant selling Provenge maker Dendreon to Chinese conglomerate for $820m

10-Jan-2017 - Sanpower Group says Dendreon's in-house manufacturing set-up will remain in place as it looks to increase US and Asian penetration of the prostate cancer cell therapy.

'Make in India' strategy to kickstart domestic biomanufacturing, Biocon

06-Dec-2016 - A lack of investment and government support has stunted biomanufacturing in India, but Biocon says this will change through the country’s 'Make in India' programme.

Thermo Fisher confident in gaining share of blossoming Korean market

01-Nov-2016 - South Korea is a key opportunity for biopharma services firms says Thermo Fisher, reporting its third quarter which saw it up capabilities in the region.

Yellow fever outbreak: Sanofi looks to double vaccine production

29-Jun-2016 - A recently opened facility will double production of Sanofi Pasteur’s vaccine Stamaril which could alleviate shortages in the wake of recent yellow fever outbreaks in parts of Africa....

Regulatory reforms to reshape drug manufacturing in China says expert

28-Jan-2016 - More plants in China will close says a US-based analyst who predicts that some drugmakers' inability to comply with stricter quality rules will create an opportunity for those that can.

Boost for Biocad's biosimilars as Russia approves first Herceptin copy

22-Jan-2016 - Russia’s first approved trastuzumab biosimilar will be priced at least 10% cheaper than Roche’s Herceptin, according to developer Biocad.

CSL opens Russian launchpad but no production plant plans in pipeline

15-Dec-2015 - CSL Behring will target growing Russian demand for protein-based therapies through a new Moscow office but says for now there are no plans for a local manufacturing site.

Filgrastim biosimilar is first Latin copy biologic, says Brazil

24-Nov-2015 - Brazilian company Eurofarma claims it has developed Latin America’s first home-grown biosimilar.

Single use

GE ships pre-built plant to China as Asia pursues homemade production

06-Nov-2015 - As GE ships the world’s largest ready-made biomanufacturing plant to China, the team involved tells us modular facilities are in demand from southeast Asian governments – and could hold the...

ISCT: $2.4bn unregulated biologics market threatens legit industry

03-Nov-2015 - The $2.4bn market for “unproven” and “unethical” biologics market “preys on vulnerable patients” and harms development of legitimate large molecule drugs, says the International Society for Cellular Therapy (ISCT).

Bioprocess International

‘Beyond revolutionary’: bioreactor-in-a-briefcase brings warzone production

27-Oct-2015 - Soldiers on the battlefield will soon be able to manufacture life-saving biologics in under eight hours using a portable briefcase-sized kit.

Sanofi blames manufacturing costs for end of snake bite cure

08-Sep-2015 - Sanofi’s decision to stop manufacturing an anti-venom will contribute to “needless death and disability” for snake bite victims, according to Médecins Sans Frontières.

Report: UK capacity for cell, gene therapy manufacturing decreases in 2015 as new projects launch

19-Aug-2015 - A surge in UK cell therapy production last year means available manufacturing capacity has declined considerably according to a report  by Cell Therapy Catapult.

$17bn Pfizer-Hospira merger approved on anti-trust conditions

05-Aug-2015 - The European Commission has approved Pfizer’s acquisition of Hospira, providing the larger company first divests of its infliximab candidate and several sterile injectables.

Novartis defends Afinitor after thrashing from BMS and Exelixis trials

22-Jul-2015 - Novartis expects sales of Afinitor to slow after BMS and Exelixis announced this week their pipeline drugs beat it on renal cell carcinoma.

Bio-Finance Vision... Baxalta, Pall and more in glorious technicolour

10-Jul-2015 - We say hello to Baxalta, ask what's the latest in Danaher's $14bn bid for Pall, and look at the latest biotech IPOs in today's Bio-Finance Vision.

BIO 2015

Does second prequalified vaccine mark China as ‘true global player’?

23-Jun-2015 - China is set to become a major vaccines manufacturer for emerging markets once it untangles some regulatory quirks, says a panel at BIO 2015. 

Netherlands to help India develop, mass produce measles-rubella vaccine

10-Jun-2015 - The Netherlands and India have signed a MOU (Memorandum of Understanding) under which a government-based institute of the Netherlands will extend technical support for the development and manufacturing of the measles-rubella...

More M&As to follow Life Technologies in 2015, says Thermo Fisher

14-Jan-2015 - Thermo Fisher says its $15bn acquisition of Life Technologies last year created cash savings it will pump into a series of aggressive M&As.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...